BioBucks Newsletter
BioBucks
Friday, 28 August, 2026
Subscribe (Free)

Upfront Briefing

Two FDA nods on the same evening, and neither was a coin flip. Roivant and Priovant got Lisraya over the line in dermatomyositis — first product, broad label, and a disease that has run on steroids since the Reagan administration. Gilead added Bixlenvo, which pairs bictegravir with lenacapavir and quietly sets up the company to compete with its own $13B blockbuster.

On the deal desk, Genentech licensed DualityBio’s DUPAC payload platform for $45M up front and north of $1B in milestones — a small cheque for a big bet on whatever comes after topoisomerase inhibitors. Elsewhere the capital markets did the heavy lifting: Moderna’s $2B zero-coupon convert, Samsung Biologics’ KRW 3T rights offering, and AusperBio’s $120M Series C.

Tape Action

Instrument Last close 1D % YTD %
S&P 500 7,731.0 +0.7% +12.7%
Nasdaq 100 29,641.6 +1.4% +17.6%
Russell 2000 3,014.3 +0.3% +20.2%
Healthcare (XLV) 171.6 (1.1%) +10.3%
Biotech (XBI) 168.2 (0.1%) +38.4%
Nasdaq Biotech (NBI) 7,319.5 (0.3%) +28.3%
Clinical Trials (BBC) 55.3 +0.3% +47.1%
  • Healthcare was the tape's only real laggard, XLV off 1.1% against a +0.7% S&P 500 — a 185bp drag — while biotech held: XBI (0.1%), NBI (0.3%), BBC +0.3%. Thursday's FDA slate landed as single-name events, with Roivant's Lisraya and Gilead's Bixlenvo giving the index no lift.
  • The broad tape ran on Nvidia, up roughly 6% after Wednesday-night results doubled annual revenue and guidance pointed to strength into 2028, dragging the Nasdaq 100 +1.4%; rates and vol stayed out of the way, with the 10-year pinned at 4.682%, VIX flat at 14.50 and TLT off 0.2%.
  • Market data: U.S. cash close Thursday, 27 August 2026.

The Big 3

1
 FDA approves Lisraya for dermatomyositis
  • The FDA approved Lisraya (brepocitinib) 30 mg, a once-daily oral TYK2/JAK1 inhibitor, for adults with dermatomyositis — the first targeted oral therapy cleared in the disease and Roivant's first marketed product.
  • Why it matters: The label is unusually broad — all adult DM patients, no restriction by disease activity, clinical presentation or prior treatment. Brepocitinib is an ex-Pfizer asset Roivant in-licensed and pushed across the line itself, in a disease that has run on high-dose steroids for decades; Priovant claims substantial steroid-sparing in the largest DM trial ever conducted. US prevalence runs 40,000–70,000, so pricing carries the revenue case rather than volume, and the drug is available immediately with a $0-copay support programme. The option value sits behind it: Phase 3 in non-infectious uveitis and cutaneous sarcoidosis, Phase 2b/3 in lichen planopilaris. JAK-class label risk is the standing overhang.
  • Source: STAT
  • More: Endpoints; Fierce Pharma
2
 Gilead's Bixlenvo clears FDA, and it competes with Biktarvy
  • The FDA approved Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg), the smallest once-daily single-tablet regimen for virologically suppressed adults with HIV, including those switching off complex multi-tablet regimens.
  • Why it matters: Approval rests on the Phase 3 ARTISTRY-1 and ARTISTRY-2 switch data first shown at CROI 2026 — comparable virologic suppression at week 48, no new safety signals, no meaningful weight effect. The commercial question is cannibalisation: Biktarvy runs roughly $13B a year and Gilead is now selling against itself in the switch segment, betting that patients cycling off nucleoside backbones are incremental rather than substitutional. This is the third lenacapavir label after Sunlenca in multidrug-resistant HIV and Yeztugo in PrEP, which is the point — Gilead is rebuilding the franchise around capsid inhibition well ahead of the Biktarvy LOE clock.
  • Source: Endpoints
  • More: Gilead; Contagion Live
3
 DualityBio, Genentech strike global ADC license pact
  • DualityBio (HKEX: 09606) signed a global collaboration and licence agreement with Genentech to build next-generation ADCs on its DUPAC novel-payload platform — $45M upfront, more than $1B in aggregate milestones, tiered royalties on net sales.
  • Why it matters: $45M is modest cash for a platform deal, which is the tell — Duality leads discovery and early global development through Phase 1a, then Genentech takes an exclusive worldwide licence and sole responsibility for everything after. DUPAC carries multiple payloads, including DUP5, DUP9 and DUP10, each with a distinct antitumour mechanism. The thesis is resistance: topoisomerase-I payloads dominate approved ADCs and are moving into earlier lines, so the refractory population is growing faster than the answer set. Roche is paying for the payload class that comes after Enhertu and Trodelvy rather than for another target. The overhang is jurisdictional — China-sourced platform, COINS Act extension to biotech still live.
  • Source: Fierce Biotech
  • More: PR

Everything Else that broke

  • FDA cleared Moderna's 2026-27 Spikevax and mNEXSPIKE formulas targeting the JN.1-lineage XFG subvariant, with doses expected in days. — PR
  • Rasonque’s $39,800 monthly list price topped forecasts and lifted launch expectations. — BioPharma Dive
  • CMS’ GLP-1 pilot is starting to show uptake and access effects for seniors. — Endpoints
  • The Fifth Circuit dealt pharma another loss in the Medicare pricing fight. — Endpoints
  • Generate Biomedicines slid after Phase 1 COPD data leaked before a European conference. — BioSpace
  • Lilly’s move to stop disclosing its Phase 1 pipeline drew mixed reviews. — Endpoints
  • Bristol Myers Squibb and RayzeBio committed more than $173M to a 225,000 sq ft radiopharma plant in Whitestown, Indiana. — Endpoints
  • At least nine September PDUFAs set up a crowded month of binary catalysts. — BioCentury
  • Evonik opened a Vancouver GMP lipid drug-delivery facility backed by over CAD 150M. — PR
  • NICE backed routine NHS funding for Bridge to Life’s VitaSmart system. — PR
  • Osivax licensed GC Biopharma's GC FLU to build a single-shot combination with its NP-targeting candidate OVX836. — Fierce Biotech
  • CEPI committed up to $16.5M to move Minapharm's Bundibugyo Ebola vaccine into the clinic against a fast-growing outbreak. — Fierce Biotech
  • Flagship's ProFound Therapeutics signed a target-discovery pact with the Gates Foundation worth up to $35M in preeclampsia. — Fierce Biotech

Deal Flow

BioBucks 2026 Deal Trackers • Updated weekly ⬇️
M&A IPO BD&L VC

M&A / BD&L

  • DualityBio licensed next-generation ADC programs to Genentech (see The Big 3). — PR
  • Osivax took a non-exclusive licence to GC Biopharma's inactivated seasonal flu vaccine GC FLU outside Japan and Korea, pairing it with OVX836 in a single-shot combination; Osivax leads development and commercialisation ex-Korea, GC Biopharma supplies the vaccine and takes royalties. Terms undisclosed. — Fierce Biotech

VC / Private Financings

  • AusperBio raised $120M in Series C to push AHB-137 through Phase 3 in chronic HBV; the round was led by an unnamed strategic investor with participation from new backer RA Capital and existing investors HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments. — PR

IPOs / Follow-Ons

  • Samsung Biologics launched a KRW 3T rights offering to fund expansion. — PR
  • Moderna launched a $2B zero-coupon convertible senior notes offering due 2032, with a $300M greenshoe and a capped call struck at a premium of at least 150%; proceeds fund the oncology business and debt repayment. Shares fell ~5%. — Endpoints

Academic Corner

  • CD19 CAR T cell therapy showed clinical improvement in all patients in a phase 1 rheumatoid arthritis trial. — Nature Medicine
That’s it for today — see you next week for the post-summer rush.
— BioBucks Team

© 2026 BioBucks.
beehiivPowered by beehiiv